Health policy

Me-too drugs with limited benefits — the tale of regorafenib for HCC

An Erratum to this article was published on 28 November 2017

This article has been updated (view changelog)

Regorafenib is only the second agent approved by the FDA for the treatment of patients with advanced-stage hepatocellular carcinoma. Herein, we discuss the evidence that led to the approval of this agent. Examination of this process reveals important challenges associated with drug regulation, relating to trial design, treatment toxicity, and real-world clinical benefit.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 28 November 2017

    In the illustration that accompanies this article, the structures of regorafenib and sorafenib were incorrectly drawn. In both structures, a double bond was omitted from the central phenyl ring so that it appeared as a 1,3-cyclohexadiene. The figure has been corrected in both the HTML and PDF versions of this News & Views.

References

  1. 1

    U.S. Food and Drug Administration. FDA expands approved use of Stivarga to treat liver cancer. FDA https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555608.htm (2017).

  2. 2

    National Cancer Institute at the National Institutes of Health. FDA approval for sorafenib tosylate. Cancer.gov https://www.cancer.gov/about-cancer/treatment/drugs/fda-sorafenib-tosylate (2013).

  3. 3

    Zhu, A. X. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 11, 790–800 (2006).

    CAS  Article  Google Scholar 

  4. 4

    Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).

    CAS  Article  Google Scholar 

  5. 5

    Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56–66 (2017).

    CAS  Article  Google Scholar 

  6. 6

    Prasad, V., Massey, P. R. & Fojo, T. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J. Clin. Oncol. 32, 1620–1629 (2014).

    CAS  Article  Google Scholar 

  7. 7

    Sanoff, H. K., Chang, Y., Lund, J. L., O'Neil, B. H. & Dusetzina, S. B. Sorafenib effectiveness in advanced hepatocellular carcinoma. Oncologist 21, 1113–1120 (2016).

    CAS  Article  Google Scholar 

  8. 8

    Gyawali, B., Shimokata, T., Ando, M., Honda, K. & Ando, Y. Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials. Ann. Oncol. 28, 246–253 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9

    Calcagno, F. et al. Efficacy, safety and cost of regorafenib in patients with metastatic colorectal cancer in French clinical practice. Clin. Med. Insights Oncol. 10, 59–66 (2016).

    CAS  Article  Google Scholar 

  10. 10

    Lee, I. C. et al. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. Medicine (Baltimore) 94, e688 (2015).

    CAS  Article  Google Scholar 

  11. 11

    He, A. R. & Goldenberg, A. S. Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations. Therap. Adv. Gastroenterol. 6, 447–458 (2013).

    Article  Google Scholar 

Download references

Acknowledgements

The work of V.P. is funded by the Laura and John Arnold Foundation to study low-value practices.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Vinay Prasad.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gyawali, B., Prasad, V. Me-too drugs with limited benefits — the tale of regorafenib for HCC. Nat Rev Clin Oncol 14, 653–654 (2017). https://doi.org/10.1038/nrclinonc.2017.100

Download citation

Further reading

Search

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing